1285429-13-1

Basic information

• Product Name: N-(3,5-dimethylbenzyl)-2-nitroaniline
• Synonyms: N-(3,5-dimethylbenzyl)-2-nitroaniline
• CAS NO: 1285429-13-1
• Molecular Weight: 256.304
• Mol File: 1285429-13-1.mol

Chemical Properties

• CAS DataBase Reference: N-(3,5-dimethylbenzyl)-2-nitroaniline(CAS DataBase Reference)
• NIST Chemistry Reference: N-(3,5-dimethylbenzyl)-2-nitroaniline(1285429-13-1)
• EPA Substance Registry System: N-(3,5-dimethylbenzyl)-2-nitroaniline(1285429-13-1)

Safety Data

• Hazardous Substances Data: 1285429-13-1(Hazardous Substances Data)

Upstream product

• 27129-86-8 1-bromomethyl-3,5-dimethylbenzene 
• 88-74-4 2-nitro-aniline 

Downstream Products

• 1562665-86-4 2-{[1-(3,5-dimethylbenzyl)-1H-benzimidazol-2-yl]sulfanyl}-N-(2-chloro-4-sulfamoylphenyl)acetamide 
• 1562666-50-5 2-amino-1-(3,5-dimethylbenzyl)aniline 
• 1562664-70-3 1-(3,5-dimethylbenzyl)-1,3-dihydro-2H-benzo[d]imidazole-2-thione 
• 1562664-78-1 2-{[1-(3,5-dimethylbenzyl)-1H-benzimidazol-2-yl]sulfanyl}-N-2-chlorophenylacetamide 
• 1562664-89-4 2-{[1-(3,5-dimethylbenzyl)-1H-benzimidazol-2-yl]sulfanyl}-N-2-bromophenylacetamide 
• 1562665-08-0 2-{[1-(3,5-dimethylbenzyl)-1H-benzimidazol-2-yl]sulfanyl}-N-2-nitrophenyl acetamide 
• 1562665-34-2 C₂₅H₂₄ClN₃OS 
• 1562665-45-5 C₂₆H₂₄ClN₃O₃S 
• 1562665-61-5 2-{[1-(3,5-dimethylbenzyl)-1H-benzimidazol-2-yl]sulfanyl}-N-[2-chloro-4-(methylsulfonyl)phenyl]acetamide 

Relevant articles and documents

Synthesis and biological evaluation of 2,3-dihydroimidazo[1,2-a] benzimidazole derivatives against Leishmania donovani and Trypanosoma cruzi

A high-throughput (HTS) and high-content screening (HCS) campaign of a commercial library identified 2,3-dihydroimidazo[1,2-a]benzimidazole analogues as a novel class of anti-parasitic agents. A series of synthetic derivatives were evaluated for their in vitro anti-leishmanial and anti-trypanosomal activities against Leishmania donovani and Trypanosoma cruzi, which have been known as the causative parasites for visceral leishmaniasis and Chagas disease, respectively. In the case of Leishmania, the compounds were tested in both intracellular amastigote and extracellular promastigote assays. Compounds 4 and 24 showed promising anti-leishmanial activity against intracellular L. donovani (3.05 and 5.29 μM, respectively) and anti-trypanosomal activity against T. cruzi (1.10 and 2.10 μM, respectively) without serious cytotoxicity toward THP-1 and U2OS cell lines.

Design and synthesis of N1-aryl-benzimidazoles 2-substituted as novel HIV-1 non-nucleoside reverse transcriptase inhibitors

A series of novel N1-aryl-2-arylthioacetamido-benzimidazoles were synthesized and evaluated as inhibitors of human immunodeficiency virus type-1 (HIV-1). Some of them proved to be effective in inhibiting HIV-1 replication at submicromolar and nanomolar concentration acting as HIV-1 non-nucleoside RT inhibitors (NNRTIs), with low cytotoxicity. The preliminary structure-activity relationship (SAR) of these new derivatives was discussed and rationalized by docking studies.

Synthesis and biological evaluation of 2,3-dihydroimidazo[1,2-a] benzimidazole derivatives against Leishmania donovani and Trypanosoma cruzi

A high-throughput (HTS) and high-content screening (HCS) campaign of a commercial library identified 2,3-dihydroimidazo[1,2-a]benzimidazole analogues as a novel class of anti-parasitic agents. A series of synthetic derivatives were evaluated for their in vitro anti-leishmanial and anti-trypanosomal activities against Leishmania donovani and Trypanosoma cruzi, which have been known as the causative parasites for visceral leishmaniasis and Chagas disease, respectively. In the case of Leishmania, the compounds were tested in both intracellular amastigote and extracellular promastigote assays. Compounds 4 and 24 showed promising anti-leishmanial activity against intracellular L. donovani (3.05 and 5.29 μM, respectively) and anti-trypanosomal activity against T. cruzi (1.10 and 2.10 mM, respectively) without serious cytotoxicity toward THP-1 and U2OS cell lines.